Lucintel Forecasts The Global Neuropathic Pain Drug Market To Reach $10 Billion By 2030

By Author: Lucintel LLC
Total Articles: 6221
Comment this article

According to a market report by Lucintel, the future of the global neuropathic pain drug market looks promising with opportunities in the hospital pharmacy, drugs store & retail pharmacy, and online pharmacy markets. The global neuropathic pain drug market is expected to reach an estimated $10 billion by 2030 from $8 billion in 2024 at a CAGR of 5.4% from 2024 to 2030. The major drivers for this market are the increasing cases of spinal stenosis and diabetic neuropathy, as well as the rise in initiatives undertaken by various government associations to enhance awareness.
A more than 150-page report to understand trends, opportunity and forecast in global neuropathic pain drug market to 2030 by drug class (antidepressants, anticonvulsant, opioids, capsaicin, and others), indication (diabetic neuropathy, spinal stenosis, chemotherapy-induced peripheral neuropathy, and others), distribution channel (hospital pharmacies, drugs stores and retail pharmacies, and online pharmacies), and region (North America, Europe, Asia Pacific, and the Rest of the World).
Lucintel forecasts that, within the drug class category, anticonvulsant ...
... is expected to witness the highest growth over the forecast period due to widespread acceptance of anticonvulsant drugs for managing neuropathic pain.
Within the distribution channel category, drug stores and retail pharmacies will remain the largest segment due to convenience in shopping being amplified by the surge in e-commerce sales, enhancements in logistics services, and the ease of payment options.
Download sample by clicking on neuropathic pain drug market.
In terms of regions, North America is expected to witness the highest growth over the forecast period due to the existence of numerous significant players in the field.
Pfizer, Eli Lilly and Company, Novartis, Mallinckrodt Pharmaceuticals, Glenmark Pharmaceuticals Limited, Teva Pharmaceuticals, Sun Pharmaceutical Industries are the major suppliers in the neuropathic pain drug market.
This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or write us at helpdesk@lucintel.com. To get access of more than 1000 reports at fraction of cost visit Lucintel's Analytics Dashboard.
About Lucintel
At Lucintel, we offer solutions for you growth through game changer ideas and robust market & unmet needs analysis. We are based in Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20 years. We are quoted in several publications like the Wall Street Journal, ZACKS, and the Financial Times.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. +1-972-636-5056
Explore Our Latest Publications
Operating Table Boot Stirrup Market
Bathroom Worktop Market
2-Bowl Kitchen Sink Market
Angiography Table Market
Baby High Chair Market